Abstract
Pirlindole is a selective MAO type A inhibitor and its clinical efficacy as an antidepressive drug has been established in several studies (this volume). The present investigation was undertaken in order to examine the following questions. First, is there any difference in the improvement of the single subscores of the depression rating scales during a period of treatment of five weeks. Second, are there any side effects of the drug when abruptly changing medication from pirlindole to a common tricyclic or tetracyclic antidepressant. Furthermore, we were interested in comparing a subgroup of responders and nonresponders with respect to possible differences in endocrine and biochemical parameters before and after three weeks of treatment with pirlindole.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R.L. Spitzer, J. Endicott, E. Robins, Research Diagnostic Criteria (RDC) for a selected group of functional disorders, 3rd edition, New York State Psychiatry Institute (1978).
M. Hamilton, A rating scale for depression, J. Neurol. Neurosurg. Psychiat. 25: 56 (1960).
J.E. Overall, D.R. Gorham, The Brief Psychiatric Rating Scale. Psychol Rep. 10: 799 (1962).
W.W.K. Zung, A self-rating depression scale, Arch. Gen. Psychiat. 12: 63 (1965).
B.J. Carrol, Implications of biological research for the diagnosis of depression, in “New Advances in the Diagnosis and Treatment of Depressive Illness”, J. Mendelwicz, ed., Elsevier, Amsterdam (1981).
W. Guy (ed.), National Institute of Mental Health, 029 DOTES. Dosage Record and Treatment Emergent Symptom Scale, in “ECDEU Assessment Manual for Psychopharmacology”, rev. ed., Rockville, Maryland (1976).
Arbeitsgemeinschaft für Methodik and Dokumentation in der Psychiatrie AMDP. Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. 3. Aufl., Springer Verlag, Berlin, Heidelberg, New York (1979).
D.V. Zerssen, D.-M. Koeller, E.R. Rey, Die Befindlichkeits-Skala (B-S)- ein einfachtes Instrument zur Objektivierung von Befindlichkeits-Störungen, insbesondere im Rahmen von Längsschnitt-Untersuchungen, Arzneimittel. - Forschung 20: 915 (1970).
M. Schmauβ, P. Meyr, Kombinationstherapie tri- und tetra- zyklischer Antidepressiva mit MAO-Hemmern, Psycho. 9: 373 (1983).
J. Anath, D. Lucins, A review of combined tricyclic and MAOI therapy, Compr. Psychiatry 18: 121 (1977)
M. Schuckit, E. Robins, J. Feighner, Tricyclic antidepressant and MAO-inhibitors, Arch. Gen. Psychiat. 24: 509 (1971).
W.A. Brown, R. Johnston, D. Mayfield, The 24-hour dexa- methasone suppression test in a clinical setting: Relationship to diagnosis, symptoms and response to treatment, Am. J. Psychiat. 136: 543 (1979).
L.Demisch, K. Syha, K. Demisch, G. Buchholz, R. Kirsten and K. Nelson, Biochemical effects of pirlindole in man, this volume
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Buchholz, G., Demisch, K., Demisch, L., Bochnik, H.J. (1985). Antidepressive Efficacy of Pirlindole in Man. In: Pichot, P., Berner, P., Wolf, R., Thau, K. (eds) Psychiatry the State of the Art. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2363-1_51
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2363-1_51
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9446-7
Online ISBN: 978-1-4613-2363-1
eBook Packages: Springer Book Archive